Everolimus in pediatric transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 5, 2012, Pages 515-519

  Pape, Lars ^a   Ganschow, Rainer ^b   Ahlenstiel, Thurid ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

everolimus; immunosuppression; pediatric kidney transplantation; survival

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN;

ADOLESCENT; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HEART TRANSPLANTATION; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; NAUSEA; ORGAN TRANSPLANTATION; PNEUMONIA; PROTEINURIA; REVIEW; WOUND HEALING IMPAIRMENT;

CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PEDIATRICS; SIROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 84866359206     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328356b080     Document Type: Review

References (29)

1. Grenda R, Watson A, Trompeter R, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant 2010; 10:828-836.
2. Gaumann A, Schlitt HJ, Geissler EK. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transplantation 2008; 21:207-217. (Pubitemid 351216959)
3. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998; 30:2200-2203. (Pubitemid 28399476)
4. Schuurmann HJ, Pally C,Weckbecker G, et al.SDZRADinhibits cold ischemiainduced vascular remodeling. Transplant Proc 1999; 31:1024-1025. (Pubitemid 29127790)
5. Matsumoto Y, Hof A, Baumlin Y, et al. Differential effect of everolimus and cyclosporin A on intimal a-actin-positive cell dynamics of carotid allografts in mice. Transplantation 2004; 78:345-351. (Pubitemid 39095399)
6. Eisen HJ, Tuzcu EM, Dorent R, et al., RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients: results at three year. N Engl J Med 2003; 349:847-858. (Pubitemid 37025404)
7. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5:671-688. (Pubitemid 44151605)
8. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6:204-312.
9. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Aktdependent prostate intraepithelial neoplasia trough regulation of apoptotic and HIF1-dependent pathways. Nat Med 2004; 10:594-601. (Pubitemid 38796850)
10. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007; 82:381-388. (Pubitemid 47414349)
11. Chapman JR, Valentine H, Abanell J, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007; 39:2937-2950. (Pubitemid 350258649)
12. Tenderich G, Fuchs U, Zittermann A, et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and hematological parameters in heart transplant recipients. Clin Transplant 2007; 21:536-543. (Pubitemid 47161833)
13. Pape L, Ahlenstiel T, Ehrich JHH, Offner G. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 2007; 11:291-295. (Pubitemid 46570146)
14. Ettenger R, Hoyer PF, Grimm P, et al., and the Everolimus Pediatric Study Group. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Pediatr Transplant 2008; 12:456-463. (Pubitemid 351652075)
15. Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose cyclosporine A, basiliximab and steroid elimination in pdiatric kidney transplantation. Am J Transplant 2010; 10:2349-2354.
16. Pape L, Lehner F, Blume C, Ahlenstiel T. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 2011; 92:658-662.
17. McDiarmid SV, Anand R, Martz K, et al. A multivariate analysis of pre, peri-, and posttransplant factors affecting outcome after pediatric liver transplantation. Ann Surg 2011; 254:145-154.
18. Chinnock TJ, Shankel T, Deming D, et al. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients. Pediatr Transplant 2011; 15:746-749.
19. Basso MS, Subramaniam P, Tredger M, et al. Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients. Pediatr Transplant 2011; 15:722-727.
20. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64:36-42. (Pubitemid 27327197)
21. Viklicky O, Zou H, Mueller V, et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 96:497-502. (Pubitemid 30129579)
22. Nielsen D, Briem-Richter A, Sornsakrin M, et al. The use of everolimus in pediatric liver transplant recipients: first experience in a single center. Pediatr Transplant 2011; 15:510-514.
23. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883-889. (Pubitemid 41552882)
24. Brinkert F, Kemper MJ, Briem-Richter A, et al. High prevalence of renal dysfunction in children after liver transplantation: noninvasive diagnosis using a cystatin C-based equation. Nephrol Dial Transplant 2011; 26:1407-1412.
25. Levy G, Schmidli H, Punch L, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results. Liver Transpl 2006; 12:1640-1648. (Pubitemid 44742543)
26. De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15:1262-1269.
27. Behmnke-Hall K, Bauer J, Thul J, et al. Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus. Pediatric Transplant 2011; 15:784-789.
28. Lehmkuhl HB, Arizon K, Vigano M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 88:115-122.
29. Bauer J, Ganschow R, Kemper MJ, et al. MTOR inhibitors-initial therapeutic experience in pediatric organ transplant recipients. Thieme Drug Rep 2009; 1:1-15.